| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 02/22/2001 | CA2382095A1 Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof |
| 02/22/2001 | CA2382019A1 Isomerase proteins |
| 02/22/2001 | CA2380642A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | CA2380432A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 02/22/2001 | CA2380373A1 Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| 02/22/2001 | CA2378332A1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | CA2377662A1 Novel protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 02/21/2001 | CN1284946A Substituted isoquinoline derivatives and their use as anticonvulsants |
| 02/21/2001 | CN1284943A Gamma-glutamyl and beta-aspartyl containing immunomodulator compounds and methods therewith |
| 02/21/2001 | CN1284865A Pharmaceutical compositions containing micronized bicyclic drugs |
| 02/20/2001 | US6191172 Used in drugs and cosmetics |
| 02/15/2001 | WO2001011041A1 MONOMERIC PROTEIN OF THE TGF-β FAMILY |
| 02/15/2001 | WO2001010865A1 p38MAP KINASE INHIBITORS |
| 02/15/2001 | WO2001010444A2 A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate |
| 02/15/2001 | WO2001010432A1 Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy |
| 02/15/2001 | WO2001010413A2 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
| 02/15/2001 | WO2001010383A2 Caspase inhibitors and uses thereof |
| 02/15/2001 | WO2001010381A2 Methods for treating or preventing pain and anxiety |
| 02/15/2001 | WO2001010203A2 Non-human transgenic animals for the study of neurodegenerative syndromes |
| 02/15/2001 | WO2000068385A3 Novel nucleic acids and proteins with growth hormone activity |
| 02/15/2001 | WO2000065054A3 Human membrane-associated proteins |
| 02/15/2001 | WO2000057920A3 Method for expressing proteins |
| 02/15/2001 | WO2000011204A3 Homer interacting proteins |
| 02/15/2001 | CA2388341A1 Non-human transgenic animals for the study of neurodegenerative syndromes |
| 02/15/2001 | CA2381215A1 P38map kinase inhibitors |
| 02/15/2001 | CA2378955A1 Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy |
| 02/15/2001 | CA2378481A1 A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate |
| 02/15/2001 | CA2377422A1 Periodic structures comprising lipids, polyelectrolytes, and structure- inducing soluble oligovalent linkers, and biological use thereof |
| 02/14/2001 | EP0968226A4 G-rich oligo aptamers and methods of modulating an immune response |
| 02/14/2001 | CN1283623A 1,2,4,5-tetrahydro-benzo[d] azepine compound |
| 02/13/2001 | US6187810 Administering to improve the therapeutic effect and the bioavailability of known medicaments; administering to diminish acute or chronic toxicity of a natural alkaloid, cardiac glycoside or synthetic drug |
| 02/13/2001 | US6187789 Muscle relaxants for emergency intubation and surgery |
| 02/08/2001 | WO2001055118A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient |
| 02/08/2001 | WO2001009346A1 Gene encoding novel adenylate kinase 3 (ak3)-like protein |
| 02/08/2001 | WO2001009320A1 Gene encoding novel adp-ribosylation factor (arf)-like protein |
| 02/08/2001 | WO2001009110A1 Novel succinate derivative compounds useful as cysteine protease inhibitors |
| 02/08/2001 | WO2001009097A1 Cyclic amine derivatives for the treatment of neurological diseases |
| 02/08/2001 | WO2001008685A1 Acyclic and cyclic amine derivatives |
| 02/08/2001 | WO2001008635A2 Calcium channel transport polynucleotides, polypeptides, and antibodies |
| 02/08/2001 | WO2001008634A2 Polynucleotide encoding a human serine protease |
| 02/08/2001 | WO2000064485A8 Specifically targeted catalytic antagonists and uses thereof |
| 02/08/2001 | WO2000058307A3 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| 02/08/2001 | CA2379993A1 Acyclic and cyclic amine derivatives |
| 02/08/2001 | CA2378929A1 Serine proteases |
| 02/08/2001 | CA2378331A1 Calcium channel transport polynucleotides, polypeptides, and antibodies |
| 02/07/2001 | EP1074620A1 Monomeric protein of the TGF-beta family |
| 02/07/2001 | EP1074256A2 Depolarizing skeletal muscle relaxants |
| 02/07/2001 | EP1074245A2 Composition using mineral salts for therapeutic treatment |
| 02/07/2001 | EP1073638A1 Heterocyclically substituted amides, their production and their use |
| 02/07/2001 | EP1073631A1 New substituted amides, their production and their use |
| 02/07/2001 | EP1073455A1 Compositions and methods for extending the action of clostridial neurotoxin |
| 02/07/2001 | CN1283200A Androfenic Steroid compounds and method of making and using the same |
| 02/07/2001 | CN1282590A 三七胶囊 Thirty-seven Capsules |
| 02/06/2001 | US6184256 Methods and compositions for use in modulating expression of matrix metalloproteinase genes |
| 02/06/2001 | US6184237 Substituted pyridine compounds and methods of use |
| 02/06/2001 | CA2314798A1 1,2,4,5-tetrahydro-benzo[d]azepin derivatives |
| 02/01/2001 | WO2001007628A2 Human synthetases |
| 02/01/2001 | WO2001007471A2 Cell cycle and proliferation proteins |
| 02/01/2001 | WO2001007470A2 Human nervous system-associated proteins |
| 02/01/2001 | WO2001007435A2 N-(indolcarbonyl-)piperazin derivatives als 5-ht2a-receptor ligands |
| 02/01/2001 | WO2001007063A1 Process for the extraction of valerian root |
| 02/01/2001 | WO2001007032A1 Th2 differentiation inhibitors |
| 02/01/2001 | WO2001006989A2 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 02/01/2001 | WO2000047194A3 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR |
| 02/01/2001 | WO2000040226A3 Method of treating sexual disturbances |
| 02/01/2001 | CA2380317A1 Human synthetases |
| 02/01/2001 | CA2379784A1 Cell cycle and proliferation proteins |
| 02/01/2001 | CA2379395A1 Process for the extraction of valerian root |
| 02/01/2001 | CA2378953A1 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 02/01/2001 | CA2375982A1 Th2 differentiation inhibitors |
| 02/01/2001 | CA2375571A1 Human nervous system-associated proteins |
| 01/31/2001 | EP1072680A1 Myostatin regulatory region, nucleotide sequence determination and methods for its use |
| 01/31/2001 | EP1072270A2 Botulinum toxins for treating dystonia |
| 01/31/2001 | EP1071655A1 Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation |
| 01/31/2001 | EP1071424A1 Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph |
| 01/31/2001 | EP1071414A1 Compounds and methods for treating mitochondria-associated diseases |
| 01/31/2001 | CN1281852A 三唑及咪唑衍生物 Triazole and imidazole derivatives |
| 01/30/2001 | US6180643 Antagonist of interleukins, tumor necrosis factor |
| 01/30/2001 | US6180370 Preparing preferential antibodies; generating nucleotide sequences coding preferential antibodies, expressing nucleotide sequences in transformed cell and recovering preferential antibodies |
| 01/30/2001 | CA2313825A1 Myostatin regulatory region, nucleotide sequence determination and methods for its use |
| 01/25/2001 | WO2001006015A1 NOVEL GLYCOSYL SULFOTRANSFERASES GST-4α, GST-4β, AND GST-6 |
| 01/25/2001 | WO2001005983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | WO2001005972A1 Compositions and methods for the treatment of immune related diseases |
| 01/25/2001 | WO2001005969A2 Electron transfer proteins |
| 01/25/2001 | WO2001005834A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | WO2001005820A2 Method for down-regulating gdf-8 activity |
| 01/25/2001 | WO2001005790A1 New compounds |
| 01/25/2001 | WO2001005776A1 Aminothiazole derivatives and their use as crf receptor ligands |
| 01/25/2001 | WO2001005772A1 Pyrazinones, compositions containing such compounds |
| 01/25/2001 | WO2001005770A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 01/25/2001 | WO2001005756A1 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors |
| 01/25/2001 | WO2001005404A1 Use of beta-napthoquinone for making medicines having an inhibiting effect on the release of glutamate by the brain |
| 01/25/2001 | WO2001005381A1 Percutaneously absorbable preparations |
| 01/25/2001 | WO2000066111B1 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions |
| 01/25/2001 | WO2000060080A3 Molecules of the immune system |
| 01/25/2001 | WO2000059940A3 Platelet-derived growth factor related gene and protein |
| 01/25/2001 | WO2000056356A3 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs) |
| 01/25/2001 | DE19934433A1 New N-(indolyl-carbonyl)-N'-ethyl-piperazine derivatives, are 5-HT-2A receptor antagonists useful e.g. for treating schizophrenia, depression, Parkinson's disease, Alzheimer's disease or anorexia |
| 01/25/2001 | CA2381327A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | CA2379983A1 Dsp-11 dual-specificity map kinase phosphatase |